Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Journal:
The Lancet Diabetes & Endocrinology
Published:
DOI:
10.1016/s2213-8587(25)00248-7
Affiliations:
9
Authors:
10
Go to article
Institutions Authors Share
Eli Lilly China, China
2.000000
 0.20
Second Affiliated Hospital of Nanjing Medical University, China
1.000000
 0.10
Zhongda Hospital, SEU, China
1.000000
 0.10
Nanjing First Hospital, China
1.000000
 0.10
Beijing Hospital, China
1.000000
 0.10
Second Affiliated Hospital, ZZU, China
1.000000
 0.10
The General Hospital, TMU, China
1.000000
 0.10
Shandong Provincial Qianfoshan Hospital (First Affiliated Hospital), SFMU, China
1.000000
 0.10
Chongqing General Hospital, China
1.000000
 0.10
Interested in Clinical Sciences?